双重STAT3/STAT5抑制作为T型多淋巴细胞白血病的新疗法
Annika Dechow1, Sanna Timonen2,3,4, Aleksandr Ianevski3
1Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf, University Hospital Cologne, Cologne, Germany.
Leukemia
|April 15, 2025
概括
新的研究确定了T型多淋巴细胞白血病 (T-PLL) 中的JAK/STAT突变. 双种STAT3/STAT5降解剂,如JPX-1244,在治疗这种侵袭性癌症方面表现有前途,特别是在组合疗法中.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- T-prolymphocytic白血病 (T-PLL) 是一种罕见的,攻击性的T细胞恶性瘤,治疗选择有限.
- 基因组和转录组分析对于理解T-PLL病原体和确定治疗点至关重要.
研究的目的:
- 研究JAK/STAT通路突变和激活在T-PLL中的作用.
- 评估双重STAT3/STAT5降解剂作为T-PLL新治疗策略的疗效.
- 确定治疗反应和有效组合疗法的预测生物标志物.
主要方法:
- 335个T-PLL病例的基因组和转录组分析.
- 对JAK/STAT突变和构成性激活的分析.
- 在实验室中对初级T-PLL细胞上的双重STAT3/STAT5降解剂 (JPX-1244) 的评估.
- 用RNA测序来评估目标基因调制.
- 与已确定的化疗剂进行组合查.
主要成果:
- 在T-PLL中发现了反复发生的JAK/STAT突变 (JAK3,STAT5B) 和构成性激活.
- JPX-1244证明了T-PLL细胞死亡的强大和选择性诱导,与STAT3/STAT5降解相关.
- 增加TOX,PAK6和SPINT1的表达预测了对STAT3/STAT5降解的敏感性.
- STAT3/STAT5降解剂与克拉迪宾,维内托克拉克斯或阿扎西提丁的组合显示出协同效果.
结论:
- 双重STAT3/STAT5抑制是T-PLL的一个有前途的治疗途径.
- 组合策略,特别是与低甲和BCL2向剂的组合策略,需要对T-PLL治疗进行进一步的临床研究.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:20The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K